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Abstract: Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal
recessive disorder which primarily affects the gastrointestinal and nervous systems. This disease
is caused by mutations in the nuclear TYMP gene, which encodes for thymidine phosphorylase,
an enzyme required for the normal metabolism of deoxynucleosides, thymidine, and deoxyuridine.
The subsequent elevated systemic concentrations of deoxynucleosides lead to increased intracellular
concentrations of their corresponding triphosphates, and ultimately mitochondrial failure due
to progressive accumulation of mitochondrial DNA (mtDNA) defects and mtDNA depletion.
Currently, there are no treatments for MNGIE where effectiveness has been evidenced in clinical
trials. This Phase 2, multi-centre, multiple dose, open label trial without a control will investigate the
application of erythrocyte-encapsulated thymidine phosphorylase (EE-TP) as an enzyme replacement
therapy for MNGIE. Three EE-TP dose levels are planned with patients receiving the dose level that
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achieves metabolic correction. The study duration is 31 months, comprising 28 days of screening,
90 days of run-in, 24 months of treatment and 90 days of post-dose follow-up. The primary objectives
are to determine the safety, tolerability, pharmacodynamics, and efficacy of multiple doses of EE-TP.
The secondary objectives are to assess EE-TP immunogenicity after multiple dose administrations and
changes in clinical assessments, and the pharmacodynamics effect of EE-TP on clinical assessments.
Keywords: mitochondrial neurogastrointestinal encephalomyopathy; MNGIE; TYMP; enzyme
replacement; erythrocyte encapsulated thymidine phosphorylase; thymidine phosphorylase;
mitochondrial disease; rare disease; orphan disease; Phase II; multiple dose
1. Introduction
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a fatal and rare autosomal
recessive disorder of nucleotide metabolism caused by mutations in the nuclear thymidine
phosphorylase gene (TYMP), which encodes cytosolic thymidine phosphorylase, the enzyme required
for the normal metabolism of pyrimidine deoxynucleosides, thymidine, and deoxyuridine [1,2].
Pathogenic variants in TYMP result in a complete or partial absence of thymidine phosphorylase
activity (<10% of healthy unaffected individuals), leading to an accumulation of thymidine and
deoxyuridine in tissues and body fluids [3–9].
Elevated systemic concentrations of these deoxynucleosides lead to increased intracellular
concentrations of their corresponding triphosphates. This perturbs the physiological equilibrium of
the deoxynucleoside triphosphate pools within the mitochondria, thereby interfering with the normal
replication of mitochondrial mtDNA, leading to multiple deletions, somatic point mutations and
depletion of mtDNA [5,8,10,11], and ultimately mitochondrial failure [5,6,8]. It is believed that the
consequent failure of cellular energy production directly causes the cardinal clinical manifestations
through damage to the nervous and muscular systems.
Patients with MNGIE usually present during the second decade of life, although patients have
presented as early as five months and as late as the fifth decade; the average age at diagnosis is
18.5 years [12]. The relatively late onset for a condition present at birth is thought to be due to the
progressive accumulation of mtDNA defects, with the disease becoming apparent once the number
of affected mitochondria reaches a critical threshold level. The disease is a multi-system disorder,
and has a characteristic, although by no means universal, clinical presentation. Patients typically
present with gastrointestinal symptoms including early satiety, nausea, dysphagia, gastroesophageal
reflux, postprandial emesis, episodic abdominal pain, episodic abdominal distention, and diarrhoea.
These symptoms are secondary to alimentary dysmotility caused by degeneration of the alimentary
autonomic nervous system [2]. Patients generally have a thin body habitus with reduced muscle
mass and cachexia. Episodes of frank intestinal pseudo obstruction may occur, and some patients
develop a hepatopathy with liver steatosis and cirrhosis. Progressive external ophthalmoplegia and
peripheral sensorimotor polyneuropathy are invariable. The latter affects the lower limbs initially
and is typically demyelinating. On magnetic resonance imaging (MRI) there is, in the majority of
cases, leukoencephalopathy with diffuse increased T2 signal in the deep white matter of the cerebral
hemispheres, but this is generally believed to be asymptomatic [5,12].
MNGIE is a progressive disease, with patients dying at an average age of 37.5 years, and at present
there are no approved therapies [4]. Allogeneic hematopoietic stem cell transplantation (HSCT) offers
the possibility of a permanent correction of the thymidine phosphorylase deficiency. However, it is still
highly experimental, carrying a mortality rate of approximately 63% [13]. Treatment with allogeneic
HSCT is limited by the availability of a matched donor, and patients are often in poor clinical condition
with impaired capacity to tolerate transplant related problems and the aggressive conditioning and
immunosuppressive chemotherapy [13,14]. The administration of HSCT to patients with MNGIE
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presents pharmacological challenges in terms of administering drugs with possible mitochondrial
toxicity, and the requirement for parenteral administration due to disturbed gastrointestinal function
and impairment of absorption. A published consensus proposal for standardising an approach
to allogeneic HSCT in patients with MNGIE recommends restricting the recruitment of patients
with an optimal donor to those without irreversible end stage disease [13,14]. Patients who are
oligosymptomatic are often reluctant to undergo HSCT due to its high mortality risk. Many patients
are therefore ineligible for this treatment option and clinical management is based on symptom relief
and palliation. A second experimental permanent treatment approach for MNGIE is orthotopic liver
transplantation. Sustained normalisation of plasma thymidine and deoxyuridine concentrations have
been reported in two patients who received liver transplantation [15]. A longitudinal evaluation of
additional transplanted patients, however, is essential to confirm the clinical efficacy of this treatment
approach. There is thus a critical requirement to develop an alternative treatment for these patients
which would provide an expeditious normalization of nucleosides to prevent as much mitochondrial
damage as possible.
The Investigational Medicinal Product under investigation in this study is erythrocyte encapsulated
thymidine phosphorylase (EE-TP), which is produced under Good Manufacturing Practice by the ex
vivo encapsulation of recombinant Escherichia coli thymidine phosphorylase into patient’s autologous
erythrocytes using an automated red cell loader device [16]. EE-TP is intravenously infused into the
patient where it aims to correct the fundamental lesion in MNGIE by replacement of the deficient
thymidine phosphorylase. The rationale for the development of EE-TP is based on thymidine and
deoxyuridine being able to diffuse across the erythrocyte membrane via nucleoside transporters into
the cytosol where the encapsulated enzyme catalyses their metabolism to the normal products, thymine
and uracil, respectively (Figure 1). The products then exit the cell into the blood plasma where they
are further metabolised as normal. It is proposed that regular intravenous (IV) administrations of
EE-TP to patients with MNGIE will lead to a sustained reduction or elimination of plasma thymidine
and deoxyuridine, leading to a clearance from the cellular compartments and thus an amelioration
of the intracellular deoxynucleotide imbalances. This should prevent further damage to mtDNA. By
relieving the nervous system and muscle of the toxic effects of the accumulated metabolites, EE-TP
aims to arrest and reverse the progression of the clinical disease.
J. Clin. Med. 2019, 8, x FOR PEER REVIEW 3 of 18 
 
HSCT to patients with MNGIE presents pharmacological challenges in terms of administering drugs 
with possible mitochondrial toxicity, and the requirement for parenteral administration due to 
disturbed gastrointestinal function and impairment of absorption. A published consensus proposal 
for standardising an approach to all geneic HSCT in patients with MNGIE recommends restricting 
the recruitment of patients wi h an ptimal d nor to those without irreve sible end stage dise se 
[13,14]. Patients wh  are oligosy ptoma ic are often reluctant to undergo HSCT due to its high 
mortality risk. Many patients are therefore ineligible for this treatment option and clinical 
management is based on symptom relief and palliation. A second experimental permanent treatment 
approach for MNGIE is orthotopic liver transplantation. Sustained normalisation of plasma 
thymidine and deoxyuridine concentrations have been reported in two patients who received liver 
transplantation [15]. A longitudinal evaluation of additional transplanted patients, however, is 
essential to confirm the clinical efficacy of this treatment approach. There is thus a critical 
requirement to develop an alternative treatment for these patients which would provide an 
expeditious normalization of nucleosides to prevent as much mitochondrial damage as possible. 
The Investigational Medicinal Product under investigation in this study is erythrocyte 
encapsulated thymidine phosphorylase (EE-TP), which is produced under Good Manufacturing 
Practice by the ex viv  encapsulation of recombinant Esch ric ia coli th midine phosphoryl se into 
patient’s autologous erythrocytes using an automated red cell loader device [16]. EE-TP is 
intravenously infused into the patient where it aims to correct the fundamental lesion in MNGIE by 
replacement of the deficient thymidine phosphorylase. The rationale for the development of EE-TP 
is based on thymidine and deoxyuridine being able to diffuse across the erythrocyte membrane via 
nucleoside transporters into the cytosol where the encapsulated enzyme catalyses their metabolism 
to the normal products, thymine and uracil, respectively (Figure 1). The products then exit the cell 
into the blood plasma where they are further metabolised as normal. It is proposed that regular 
intravenous (IV) administrations of EE-TP to patients with MNGIE will lead to a sustained reduction 
or elimination of plasma thymidine and deoxyuri ine, leadi g to a clearance from the cellular 
compartme ts and thus an amelio tion of the intra l r deoxynucleotide imbalances. This should 
prevent further damage to mtDNA. By relieving the nervous system and muscle of the toxic effects 
of the accumulated metabolites, EE-TP aims to arrest and reverse the progression of the clinical 
disease. 
 
Figure 1. Mechanism of erythrocyte encapsulated thymidine phosphorylase (EE-TP) action. Plasma 
thymidine and deoxyuridine diffuse across the erythrocyte membrane via nucleoside transporters 
into the erythrocyte cytosol where the encapsulated thymidine phosphorylase (TP) catalyses their 
metabolism to thymine and uracil, which then exit the erythrocyte to enter the normal metabolic 
pathways. 
Figure 1. Mechanism of erythrocyte encapsulated thymidine phosphorylase (EE-TP) action. Plasma
thymidine and deoxyuridine diffuse across the erythrocyte membrane via nucleoside transporters into
the erythrocyte cytosol where the encapsulated thymidine phosphorylase (TP) catalyses their metabolism
to thymine and uracil, which then exit the erythrocyte to enter the normal metabolic pathways.
EE-TP has the advantage of prolonging the circulatory half-life of the enzyme to that of the
erythrocyte half-life (19–29 days) and minimising immunogenic reactions, which are often observed in
enzyme replacement therapies administered by the conventional route.
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Clinical experience with EE-TP is limited to a proof-of-concept study in a single patient diagnosed
with MNGIE and a compassionate clinical evaluation in four patients with MNGIE [17–19]. EE-TP
was well tolerated and reductions in the disease-associated plasma metabolites, thymidine and
deoxyuridine, were observed in all patients. Clinical improvements were observed in three patients
who received long-term treatment, suggesting that EE-TP is able to reverse some aspects of the disease
pathology. Transient, non-serious adverse events were observed in two of the five patients; these did
not lead to therapy discontinuation and were managed with pre-medication prior to infusion of EE-TP.
Despite using an E. coli recombinant protein, specific anti-thymidine phosphorylase antibodies were
detected in only one patient.
The aim of this study is to investigate the safety, tolerability, pharmacodynamics, and efficacy
of EE-TP in patients with MNGIE. We hypothesise that treatment with EE-TP will arrest and reverse
the progression of the clinical disease. The study protocol reported here (version 6.0) was written in
compliance with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)
2013 [20]. The sponsor, St George’s, University of London, requested scientific assistance for EE-TP and
the current protocol was updated in line with the European Medicines Agency (EMA) advice provided.
The study will be conducted in accordance with the following and all subsequent amendments: (i)
International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals
for Human Use (ICH) E6: Good Clinical Practice: Consolidated guideline Committee for Proprietary
Medicinal Products (CPMP)/ICH/135/95 (July 1996), adopted in the EU by CPMP, (ii) European
Commission Directive 2001/20/EC (April 2001), (iii) European Commission Directive 2003/94/EC
(October 2003), (iv) European Commission Directive 2005/28/EC (April 2005), (v) Manufacture of
Investigational Medicinal Products: Volume 4, Annex 13 of the EU Guidelines to Good Manufacturing
Practice (February 2010), and (vi) The Medicines for Human Use (Clinical Trials) Regulations 2004 and
all subsequent amendments.
2. Methods
2.1. Trial Objectives
The primary objectives of this study are to determine the safety, tolerability, pharmacodynamics,
and efficacy (as measured by weight stabilisation) of multiple doses of EE-TP in patients with MNGIE.
The secondary objectives are to assess the immunogenicity of EE-TP after multiple dose administrations,
evaluate changes in clinical assessments, and assess the pharmacodynamics effect of EE-TP on clinical
assessments. Additional exploratory objectives aim to evaluate the effects of EE-TP on serum and
plasma markers of mitochondrial condition, MRI (brain), abdominal ultrasound, electromyography,
and neuro-ophthalmological assessments.
2.2. Study Drug
EE-TP will be prepared by trained personnel using an automated red cell loading process at
each trial site according to the Red Cell Loader protocol. A predetermined volume of the patient’s
blood (120 to 360 mL) will be removed from the patient and then introduced into the Red Cell Loader,
which separates the blood components and then subjects the erythrocytes to a reversible hypo-osmotic
dialysis process. Under hypo osmotic conditions, the erythrocytes swell due to an influx of water and
at a critical size, pores form in the membrane. Whilst in a permeable state, the study drug, thymidine
phosphorylase, enters the erythrocytes by diffusion. The permeability was reversed by restoration of
iso-osmotic conditions, encapsulating the thymidine phosphorylase within the erythrocytes, to form
EE-TP. The EE-TP will be dispensed into a sterile European Pharmacopoeia grade 100 mL capacity
blood transfer bag and released as multiple units (2–6 bags, the number depending on the dose to
be administered) for infusion within 30 min of manufacture. Characteristics of EE-TP are shown in
Table 1.
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Table 1. Characteristics of EE-TP.
EE-TP Attributes Criteria
Dosage Form ~58–65 × 1010 erythrocytes suspended in saline
Thymidine-phosphorylase/erythrocytes ratio ~30–90 U/1010 erythrocytes
Dosage Volume ~150–500 mL
Route of Administration IV
Physical Description Light to dark red color, resembling venous blood
EE-TP—erythrocyte encapsulated thymidine phosphorylase; IV—intravenous.
2.3. Trial Design
The trial is a Phase 2, multi-centre, multiple dose, open label trial without a control which will be
conducted in a maximum of five sites in Europe and Israel, with all patients receiving EE-TP. For each
patient, the overall study duration will be 31 months, consisting of a 28 day screening phase, a 90 day
run-in phase, a 24 month open-label treatment phase, and a 90 day follow-up phase. A schematic of
the proposed study design is presented in Figure 2.
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Figure 2. Study Design Schematic. The overall study duration will be 31 months, comprising 28 days
screening, 90 days run-in, 24 months open label treatment and 90 days post-dose follow-up. The first 4
treatment cycles will be administered every 21 days, with patients receiving Dose Level 1 for the first
2 treatment cycles. If metabolic correction is not achieved, the subsequent 2 treatment cycles will be
administered at Dose Level 2. From treatment day 78, a flexible osing a proach will be employed
to achieve m tabolic correction, whe inistration will be at Dose Levels 1, 2 or 3, once every
2–4 weeks ays until th end of the study.
Patien s will be screen d for elig bil ty from Da 0 to Day −92. If eligible, patients will then
enter the run-in period, from Day −91 to pre- ose o ay 0, in which key aspects of their overall
clinical condition and metabolite levels will be recorded. The variability in these clinical and metabolic
parameters is currently unknown, and these data will primarily serve to act as each patient’s own
pre-treatment/control observations.
Prior to entering the treatment phase, patients will attend the study site for pre-treatment
assessments and to determine continued study eligibility either the day before dosing (Day –1) or
in the morning of the day of dosing (Day 0). For the first four treatment cycles, the administration
will be every 21 days, with the administration of EE-TP at the same time of day (±2 h). The first dose
(Treatment Cycle 1) of EE-TP will be administered on day 0, with subsequent doses on D ys 21, 42, and
63 (Tr atment Cycles 2, 3 and 4, re pectively). For Tr a ment C cles 1, 2, 3, and 4, patients will leave
the study site following dosing and retur the next day (Days 1, 22, 43, and Day 64, respectively) for
24 h post-dose assessments. The planned dose levels are presented in Table 2. All patients will receive
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infusions at Dose Level 1 (~58–65 × 1010 erythrocytes encapsulating ~30–49 U TP/1010 erythrocytes)
for the first 2 treatment cycles (Treatment Cycles 1 and 2). If metabolic correction (defined as plasma
thymidine <3 µmol/L and deoxyuridine <5 µmol/L, i.e., below the diagnostic levels for MNGIE) is not
achieved, the subsequent 2 treatment cycles (Treatment Cycles 3 and 4) will be administered at Dose
Level 2 (~58–65 × 1010 erythrocytes encapsulating ~50–69 U TP/1010 erythrocytes).
Table 2. Dose levels of EE-TP.
Dose Level Erythrocyte Number and Thymidine Phosphorylase Activity (U *)
1 (low dose) ~58–65 × 1010 erythrocytes encapsulating 30–49 U TP/1010 erythrocytes
2 (mid dose) ~58–65 × 1010 erythrocytes encapsulating 50–69 U TP/1010 erythrocytes
3 (high dose) ~58–65 × 1010 erythrocytes encapsulating 70–90 U TP/1010 erythrocytes
* 1 unit of activity is defined as as the amount of enzyme required to convert 1 µmol of thymidine to thymine per
min at 37 ◦C.
From Day 78, the dose will remain at the dose that achieved metabolic correction during the initial
treatment phase (pre-Day 78). If metabolic correction was not achieved, treatment will advance to
Dose Level 3 (~58–65 × 1010 erythrocytes encapsulating ~70–90 U TP/1010 erythrocytes) for subsequent
treatment cycles. It is planned that patients will receive EE-TP every 2–4 weeks ± 2 days until the end of
the study. Dose frequency may be reduced (e.g., from every 2 weeks to every 3–4 weeks) for individual
patients based on emerging safety, tolerability, efficacy, and pharmacodynamics data. The interval
between doses will not be shorter than 2 weeks ± 2 days. In the advent of an increase in plasma
metabolite levels, the frequency of dosing and/or dose level will be reviewed and adjusted accordingly.
The study will be flexible; continued pharmacodynamic assessment will enable dose optimisation
and further inform dose response models and establish the therapeutic window for the treatment.
A Patient Oversight Committee will perform ongoing reviews of safety, tolerability, efficacy, and
available pharmacodynamic data to ensure the acceptability of continued dosing and/or dose
progression for each patient. An overview of the dosing scheme is presented in Figure 3.
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Figure 3. Planned dosing scheme durin treatment phase. All pa ients will r ceive i fusions
at Dose Level 1 f r t e first 2 treatment cycles (Treatment Cycles 1 and 2). If metabolic correction
is not achieved, the subsequent 2 treatment cycles (Treatment Cycles 3 and 4) will be administered
at Dose Level 2. If metabolic correction is not achieved, treatment will advance to Dose Level 3 in
Treatment Cycles 5 and 6. If metabolic correction is not achieved after Treatment Cycle 6 at Dose Level
3, the Independent Data Monitoring Committee (IDMC) will provide recommendations on the need for
dosing modifications.
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2.4. Participants
The study will enrol 12 adult male or female patients with MNGIE, aged 18 years or above,
of any race and who have received no previous treatments. An additional 8 juvenile patients will
be enrolled following an Independent Data Monitoring Committee review of an interim analysis of
safety data safety and tolerability data. Up to four patients aged 16 years or older may be dosed at
the lowest level after 24 patient-months of exposure in patients aged 18 years or over. The starting
dose will be Dose Level 1 for both groups, with escalation to the next dose level as described for the
adult cohort. Up to four patients aged 12 years or older may be dosed at the lowest dose level (Dose
Level 1) after 24 patient-months of exposure in patients aged under 18 years. Juvenile cohorts may
escalate to a higher dose or de-escalate to a lower and/or intermediate dose level(s) of EE-TP previously
administered. Screening failures and patients withdrawing from the study may be substituted with
Independent Data Monitoring Committee recommendations.
2.4.1. Study Inclusion Criteria
1. Patients must be aged 18 years or older. The age range will be extended to include:
(i) Patients aged 16 years or older after 24 patient-months of exposure in those aged 18 years
or over;
(ii) Patients aged 12 years or older after 24 patient-months of exposure in patients aged under
18 years of age at the time of enrolment.
2. Patients must be diagnosed with MNGIE by demonstrating all of the following:
(i) <18% normal thymidine phosphorylase activity in the buffy coat;
(ii) >3 µmol/L plasma thymidine;
(iii) >5 µmol/L plasma deoxyuridine;
(iv) Confirmation of the presence of biallelic pathogenic variants in TYMP by sequencing.
3. Patients must be able to undergo study procedures.
4. Patients must agree to either remain completely true abstinent or to use 2 effective contraceptive
methods from Screening until completion of the Follow-up Visit.
5. Patients must be willing to sign and date the written Informed Consent Form.
2.4.2. Study Exclusion Criteria
6. Patients who have received a successful liver or bone marrow transplant.
7. Patients suitable for allogeneic HSCT.
8. Patients with a matched allogeneic HSCT donor.
9. Patients with a history of human immunodeficiency virus, hepatitis B infection, or an active
hepatitis C infection.
10. Patients who are severely disabled or with a life expectancy of less than 12 months at Screening
based on the opinion of the investigator.
11. Female patients who are:
(i) Pregnant, planning a pregnancy, or are unwilling to use contraception;
(ii) Breastfeeding or lactating.
12. Patients who have donated blood in the 90 days prior to Screening.
13. Patients with a confirmed red blood cell count of <3.0 × 109 per mL.
14. Patients who have a significant history of alcoholism or drug/chemical abuse within 1 year prior
to Screening based on the opinion of the investigator.
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15. Patients who have an abnormality in heart rate, blood pressure, or body temperature at Screening
that increases the risk of participating in the study based on the opinion of the investigator.
16. Patients who have an abnormality in the 12-lead electrocardiogram at Screening that increases
the risk of participating in the study based on the opinion of the investigator.
17. Patients who have, or have a history of, any clinically significant neurological, gastrointestinal,
renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine, haematological, or
other major disorder (except for disorders associated with MNGIE that do not constitute a risk
when taking the study drug and would not interfere with the study objectives) based on the
opinion of the investigator.
18. Patients with any current malignancy, or a history of malignancy within 5 years prior to Screening,
with the exception of adequately treated or excised non-metastatic basal cell or squamous cell
cancer of the skin or cervical carcinoma in situ.
19. Patients who are currently enrolled in, are planning to participate in, or have discontinued within
the last 30 days from a clinical study involving an investigational medicinal product or are
concurrently enrolled in medical research judged not to be scientifically or medically compatible
with EE-TP.
20. Patients with any medical condition which would make the patient unsuitable for enrolment
or could interfere with the patient’s participation in, or completion of, the study based on the
opinion of the investigator.
2.5. Interventions
2.5.1. Preparation and Administration of Erythrocyte Encapsulated Thymidine Phosphorylase (EE-TP)
On the morning of each treatment cycle patients will undergo venesection for the collection of
120–360 mL of blood for the manufacture of EE-TP. The volume of blood collected will be dependent
on the patient’s haematocrit, red cell count, and the dose of EE-TP to be administered. EE-TP will be
administered as an intravenous infusion, within 30 min of the completion of manufacture, according
to the specified study protocol, using a standard intravenous infusion set with a micro-aggregate
filter in-line.
2.5.2. Assessments
The following information will be recorded for all potential patients as part of the screening
assessments: Informed consent, inclusion/exclusion criteria, demography, including sex, race and age,
medical history, and concomitant medication use (Table 3).
Each patient will be required to undergo the following assessments during the screening and run-in
phases (Table 3) and treatment and follow-up phases (Table 4) at the study times indicated: Vital signs
measurement, 12-lead electrocardiogram (ECG), body weight (kg) and height (m), physical examination,
pregnancy test (female patients only), adverse event recording, total parenteral nutrition (TPN) use,
handgrip strength using handgrip dynamometry, disability measured using the Rasch built Overall
Disability Scale (RODS), ambulatory function measured using the 10 m walk test, gastrointestinal
symptoms (abdominal pain, diarrhoea, disrupted swallowing, gas and bloating, gastroesophageal
reflux, and nausea and vomiting) measured using the Patient-Reported Outcomes Measurement
Information System (PROMIS) short form scales, distal sensory impairment and areflexia or motor
strength using neurological examinations, MRI brain, abdominal ultrasound, nerve conduction studies
and electromyography, neuro-ophthalmology and quality of life measured using EuroQol 5 Dimension
(EuroQol-5D), Clinical Global Impression-Improvement Scale (CGI-I), Patient Global Impression of
Change (PGIC), and visual analogue scale (VAS) for determining the severity of the patient’s most
disabling symptom.
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Table 3. Schedule of assessments from screening to the end of the run-in phase.
Assessment
Screening
(Day −120 to Day −92)
Run-in Period
(Day −91 to Day 0)
Day −91 to −84 Mid Run-in Day −1 to 0
Informed consent X
Inclusion/exclusion criteria X
Demographics X
Medical history X X
Anthropometrics 1 X X X X
Viral serology X
Pregnancy test 2 X
Serum follicle-stimulating hormone 2 X
TYMP analysis X
Leucocyte TP activity X
Patient emergency card X
RBC count X X X
Vital signs X X
12-lead ECG X X
Clinical laboratory evaluations 3 X X X X
Haematocrit X X
Physical examination X X X
Plasma thymidine and deoxyuridine X X X X
Urine thymidine and deoxyuridine X X X X
BMI X X X
Handgrip dynamometer X X X
RODS X X X
10-metre walk test X X X
EuroQol-5D X X
PGIC X X
CGI-I X X
PROMIS X X X
VAS 4 X X X
TPN use X X X
Neurological examination X X
MRI (brain) X X
Abdominal ultrasound X X
Nerve conduction and electromyography 5 X X
Neuro-ophthalmological assessment X X
FGF-21, GDF15, and other markers of
mitochondrial condition X X
1 For adult patients, height will be measured at the beginning of run-in period. For juvenile patients, height
will be measured with weight at all time points. 2 Female patients only; pregnancy test at Day 0 (Treatment
Cycle 1) to be conducted prior to study drug administration. 3 Serum biochemistry: Alanine aminotransferase,
aspartate aminotransferase, alkaline phosphatase, albumin, gamma glutamyl transferase, sodium, potassium,
chloride, calcium, magnesium, inorganic phosphate, glucose (non-fasting), urea, uric acid, total bilirubin, direct
bilirubin, creatine kinase, iron, ferritin, folate, vitamin b12, total protein, cholesterol (including total, low density
lipoprotein, and high density lipoprotein), triglycerides, lactate dehydrogenase, c reactive protein, and creatine
kinase. Haematology: white blood cell count, red blood cell count, red cell distribution width, haemoglobin,
haematocrit, mean cell volume, mean cell haemoglobin, mean cell haemoglobin concentration, platelet count,
white blood cell differential, international normalised ratio, CD4+, and CD8+. 4 At screening the investigator and
patient will identify the patient’s most disabling symptom. 5 Sensory bilateral nerves: Median, ulnar, radial, sural,
and superficial peroneal; motor bilateral nerves: Median, ulna, common peroneal, and post tibial; EMG: Dorsal
interosseous, tibialis anterior, and gastrocnemius bilateral muscles.
2.5.3. Clinical Laboratory and Pharmacodynamic Evaluations
Blood and urine samples will be collected for haematology, serum biochemistry and urinalysis
evaluations and for the longitudinal monitoring of thymidine and deoxyuridine concentrations at
the times indicated in Tables 3 and 4. Blood samples will also be collected for the measurement of
anti-thymidine phosphorylase antibodies and neutralizing antibodies, and for the exploratory analysis
of fibroblast growth factor 21 (FGF21), growth differentiation factor 15 (GDF15), mtDNA, messenger
RNA (mRNA), microRNA (miRNA), and lipidomics, proteomics, and other markers of mitochondrial
condition (Tables 3 and 4).
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Table 4. Schedule of assessments during the treatment and follow-up phases.
Assessment
Study Day
0
TC 1 1 7 14
21
TC 2 22 28 35
42
TC 3 43 49 56
63
TC 4 64 70 77
Every 2–4
Weeks up to
24 Months
Follow-Up
90 Days
Post-Dose
Pregnancy test 1 X X X X X
RBC count X X X
Administration of Study Drug X X X X X
Adverse event recording Ongoing during the study
Concomitant medication 2 Ongoing during the study
Vital signs X X X X X X X X X X X X
12-lead ECG X X X X X X X X X X X X
Clinical laboratory evaluations 3 X X X X X X X X
Physical examination X X X X X
Anti-TP antibody/neutralising
antibodies X X X X X
Plasma thymidine and
deoxyuridine X X X X X X X X X X X X
4 X
Urine thymidine and deoxyuridine X X X X X X X X X X X X X 5 X
Body weight and height X X
BMI X X
Handgrip dynamometer X X X
RODS X X X
10-metre walk test X X X
EuroQol-5D X X X
PGIC X X X
CGI-I X X X
PROMIS X X X
VAS symptom X X X
TPN use X X X
Neurological examination X X
MRI (brain) X 6 X
Abdominal ultrasound X 6 X
Nerve conduction and
electromyography 7 X
6 X
Neuro-ophthalmological
assessment X
6 X
FGF21, GDF15, and other markers
of mitochondrial condition X X X X X X X X X X X X X X X X X
1 Female patients only will be assessed at every 4 weeks. 2 Medication will be assessed for potential mitochondrial toxicity. 3 As reported in Table 4. 4 For the first 6 months, patients will
return for an additional analysis of plasma thymidine and deoxyuridine at 7 days post-dose of every other treatment cycle. For rest of dosing, patients will return for an additional analysis
of plasma thymidine and deoxyuridine at 7 days post-dose once every 4 treatment cycles. 5 24 h urine collection for creatinine, thymidine, and deoxyuridine excretion will start from 6 days
post-dosing for 24 h at every 4 treatment cycles. 6 Performed at 12 and 24 months. 7 As reported in Table 3. TC—treatment cycle.
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2.6. Trial Endpoints
2.6.1. Efficacy Endpoints
The primary efficacy endpoint will be the mean absolute change from baseline in body mass index
(BMI) at 24 months. The secondary efficacy endpoints will be the mean absolute change from baseline
in BMI at Day 63 and 3, 6, 9, 12, 15, 18, and 21 months, plus the change from baseline at 63 days and 3,
6, 9, 12, 15, 18, 21, and 24 months in: (i) The proportion of patients who require TPN; (ii) Handgrip
dynamometry; (iii) RODS; (iv) 10 m walk test; (v) EuroQo-5D; (vi) CGI-I; (vii) PROMIS short form
scales; (viii) PGIC; (ix) Neurological examination tests; and (x) VAS for the most disabling symptom.
2.6.2. Safety Endpoints
The clinical safety of EE-TP will be evaluated by: (i) The incidence, frequency, and severity of
adverse events (or treatment-emergent adverse events); (ii) The incidence of laboratory abnormalities,
based on haematology, serum biochemistry, and urinalysis test results; (iii) Vital sign measurements
(systolic and diastolic blood pressure, pulse rate, respiratory rate, and body temperature); (iv) 12 lead
ECG parameters; (v) Physical examination findings; and (vi) The use of concomitant medication(s).
2.7. Sample Size
The sample size for this study is dictated by the rarity of the condition and not by any quantitative
statistical considerations or formal sample size calculations. At least 12 adult treatment naïve patients
will be treated in this study, with the option to enrol an additional 8 juvenile patients, beyond this
original set of 12 patients.
2.8. Statistical Analyses
Statistical analyses will be primarily descriptive. Analyses will be performed using Statistical
Analysis Software® (Version 9.2 or higher, SAS Institute, Cary, NC, USA). For continuous data,
summary statistics will include the arithmetic mean, arithmetic standard deviation, median, lower and
upper quartiles, plus minimum, maximum, and number. For log normal data, summary statistics,
including the geometric mean and geometric coefficient of variation, will also be presented. For
categorical data, frequency counts and percentages will be presented. Data listings will be provided
for all patients up to the point of withdrawal, with any patients excluded from the relevant population
indicated. For the calculation of summary statistics and statistical analysis, unrounded data will
be used.
For each study participant the change from baseline will be calculated by subtracting their mean
baseline value from the value at the specific time point. The mean change from baseline will be derived
as the arithmetic mean of all individual patients’ change from baseline values.
2.8.1. Safety Data Analysis
A baseline sign and symptom will be defined as an adverse event that starts after the patient
has provided written informed consent and resolves prior to the first treatment cycle. It will also
be defined as an adverse event that starts prior to the first treatment cycle and does not increase in
severity after dosing. A treatment emergent adverse event will be defined as an adverse event that
occurs post-dose or that is present pre-dose and becomes more severe post-dose. Treatment emergent
adverse events will be summarised by dose level, maximum severity, and relationship to the study
drug. The frequency of treatment emergent adverse events plus the number and percentage of patients
experiencing a treatment emergent adverse event will be summarised by dose level, the Medical
Dictionary for Regulatory Activities system organ class, plus preferred term. A frequency summary
will be presented by day of onset across the multiple dosing period.
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Vital signs, serum biochemistry, haematology, and urinalysis data will be summarised by dose
level, together with changes from the baseline. All serum biochemistry, haematology, and urinalysis
data outside the clinical reference ranges will be listed by parameter and treatment. ECG data, including
QTc, QTcB, QTcF, the PR and QT intervals, QRS duration, and heart rate, will be obtained directly from
the 12-lead ECG traces. The ECG data will be summarised by dose level. Values for ECG parameters
outside the clinical reference ranges will be indicated on the individual patient data listings. Physical
examination and concomitant medication data will be listed.
2.8.2. Pharmacodynamic Data Analysis
The absolute values and changes from baseline urine and plasma concentrations of thymidine
and deoxyuridine will be calculated using Day 0 or Day 1 as the baseline. The proportion of patients
who achieve metabolic correction (plasma thymidine <3 µmol/L and deoxyuridine <5 µmol/L) will
be presented by dose. The activity of thymidine phosphorylase administered will be calculated for
each treatment cycle and longitudinal changes will be plotted. The presence of specific anti-thymidine
phosphorylase antibodies will be recorded.
2.8.3. Efficacy Data Analysis
The changes from baseline for all efficacy endpoints and outcomes will be calculated using data
from the run-in period (Day −91 to Day 0) as the baseline. Absolute and percentage changes from
baseline in BMI will be plotted. In addition, absolute and percentage changes from baseline in BMI will
be recorded against plasma and urine concentrations of thymidine and deoxyuridine. The percentage
of patients achieving at least the minimum threshold of weight gain will be presented by dose. Since
juvenile patients in the juvenile cohorts will be developing (i.e., growing and maturing) during the
study, changes in weight and other efficacy endpoints cannot be reliably attributed to EE-TP, and
therefore their data will not be included in the main efficacy analyses, and will be analysed separately.
2.8.4. Exploratory Data Analysis
Overall change from baseline to 12 and 24 months, categorised as improved, stable, and
deteriorated, will be carried out at the following clinical assessments: (i) MRI (brain); (ii) Abdominal
ultrasound; (iii) Nerve conduction studies and electromyography; and (iv) Neuro ophthalmological
assessment. In addition, changes from baseline in serum or plasma biomarkers related to mitochondrial
health such as FGF 21, GDF15, and other markers of mitochondrial condition at Days 0, 1, 7, 14, 21, 28,
35, 42, 43, 49, 56, 63, 64, 70, and 77, and at each clinic visit from Day 78 until the end of the study, will
be recorded. Associations between pharmacodynamics parameters and clinical activity parameters
will be explored.
2.8.5. Interim Analysis
An interim review of data will be conducted after each of the twelve-adult treatment naïve patients
has been exposed to EE-TP for at least one year. This interim time point has been chosen to assess and
confirm the potential utility of EE-TP in this population, and to provide potential early access of EE-TP
in this population. The exposure for a patient at the interim stage could exceed one year if a patient is
recruited early on into the study.
2.9. Data Monitoring Committee
The appointed Independent Data Monitoring Committee will oversee safety throughout the trial
period. The committee will comprise a chairperson, a specialist in MNGIE, and a statistician. The
purpose of the committee will be to review unblinded study information including protocol violations,
patient withdrawals, adverse/serious adverse events, and laboratory data. An assessment will be made
by the Independent Data Monitoring Committee with regard to the enrolment of juvenile patients.
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2.10. Patient Confidentiality
Patient confidentiality will be held by the participating investigators and all personnel involved
at the study sites. Following Good Clinical Practice principles, a patient number will be used to
identify the patient in the study records. Laboratory samples and any samples in storage will be
labelled using only the patient number, and the identity of the patient will be known only by the
study site. The numbering code associated with the labels will be held by the study sites, thereby
allowing no unwarranted access to the information. When reporting results for any interim safety
information, analyses, and end of the study, the code will be shared as per sponsor standard operating
procedures. The numbering code will also be held for any samples in storage until marketing approval
in the countries where the study is conducted, or until notification is received that storage is no
longer required.
2.11. Dissemination
The results of this study will be disseminated through presentation at international scientific
conferences and reported in peer-reviewed scientific journals. We also intend to disseminate our results
to the rare disease community.
2.12. Ethical Conduct and Approval and Trial Registration
This study will be conducted in accordance with consensus ethics principles derived from the
Declaration of Helsinki. Approval for the operation of the clinical trial at the United Kingdom study
site was granted following Research Ethics Committee review (18/SW/0266) and Health Research
Authority (HRA) and Health and Care Research Wales (HCRW) review. For the non-United Kingdom
trial sites, the study will be considered by the relevant Ethics Committee (EC) of each participating
country site.
2.13. Trial Registration and Status
The trial is registered at ClinicalTrials.gov, with identifier number NCT03866954. The trial is in
preparation and is not yet open for participant recruitment.
3. Discussion
Mitochondrial neurogastrointestinal encephalomyopathy is a relentlessly progressive disorder
with an invariably fatal outcome, and therefore an early diagnosis and subsequent normalisation
of deoxynucleosides is critical to avoid ongoing mitochondrial damage and disease progression.
The compassionate treatment of patients with regular infusions of EE-TP demonstrated a reduction or
elimination of plasma deoxynucleosides and clinical improvements in patients who received long-term
treatment, suggesting that EE-TP is able to reverse some aspects of the disease pathology [18,19].
This study aims to determine the safety, tolerability, pharmacodynamics, and efficacy of multiple doses
of EE-TP in patients with MNGIE. In practice, treatment with EE-TP is likely to be sought for patients
in whom the risk of mortality from allogeneic HSCT would be too high, and also for those for whom
there is no matched donor. Treatment with EE-TP may also be indicated as a rescue or maintenance
therapy prior to the availability of a suitable HSCT donor, and for patients who are oligosymptomatic
and reluctant to undergo HSCT.
The total sample size of 12 adult treatment naïve patients is not based on a formal statistical
calculation; it is a relatively small sample size, but this is expected to be offset by the nature of
the condition. MNGIE has a predictable clinical course; it is relentlessly progressive, with a very
poor prognosis for life, and it has been reported that the mean age of death is 37.6 years (range
15–54 years) [21]. Therefore, any arrest or improvement of patients’ clinical deficits and/or reduction in
mortality should be conspicuous and would not be plausibly explained by factors other than treatment
with EE-TP. Clearly, such findings would be highly clinically relevant.
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The rationale for the dose selection is based on data generated from patients who received EE-TP
on a compassionate treatment basis. This indicated that the optimal parameters required to achieve
metabolic depletion of thymidine and deoxyuridine were a maximum of 90 U TP/1010 erythrocytes
and a minimum 58 × 1010 erythrocytes. We therefore propose the infusion of an optimum number of
~58–65× 1010 erythrocytes at three dose levels: 30–49, 50–69 and 70–90 U/1010 erythrocytes. The starting
dose for all patients will be Dose Level 1; this will be administered for at least two treatment cycles
(three weeks apart). This initial three week period has been designed to ensure metabolic correction
is captured appropriately, and dosing changes can be made accordingly. If metabolic correction is
observed, the patient will continue to receive this same low dose. However, if no metabolic correction
is observed then the patient will receive Dose Level 2 (mid dose level) for two consecutive treatment
cycles. If metabolic correction is still not achieved, treatment will advance to Dose Level 3 (high dose)
for subsequent treatment cycles. Both dose and dosing regimens will be flexible.
The study will be open label with a three month run-in period, which is appropriate, as the
primary objective is to evaluate the safety, tolerability, efficacy, and pharmacodynamics of EE-TP in
patients with MNGIE. Currently, it is not known how variable or what change, if any, in the clinical
and metabolic parameters will be observed over this three month run-in period, but these data will
primarily serve to act as each patient’s own pre-treatment/control observations. Patients with MNGIE
present with a wide variety of clinical (gastrointestinal and neurological) features and these data are
highly likely be very heterogeneous between patients. Nonetheless, prolonged treatment with EE-TP
is expected to cause positive changes in these various clinical and metabolic endpoints. The decision
not to include a placebo control group was taken due to the serious and life-threatening nature of the
disease and the evidence available from compassionate treatment data for EE-TP to mediate metabolic
correction of thymidine and deoxyuridine levels in patients with MNGIE. Based upon pre-clinical
data and compassionate treatment data, the 24 month duration of the study is considered sufficient to
assess the safety and tolerability, and to establish the pharmacodynamic effects of EE-TP. There is very
limited natural history data available for MNGIE, and no clinical study data to determine the duration
of treatment required to detect potential treatment effects. An interim review of open label data will be
conducted after each of the 12 adult treatment naïve patients have been exposed to EE-TP for at least
one year.
The rationale for the pharmacodynamic objective is based on the biochemical hallmark of MNGIE,
where the deoxynucleosides thymidine and deoxyuridine accumulate in the plasma as a result of
the deficient thymidine phosphorylase. The accumulation of thymidine impacts deoxynucleoside
and nucleotide pools, and is thought to impede mtDNA replication and/or repair leading to mtDNA
abnormalities and ultimately, mitochondrial dysfunction. Erythrocyte encapsulated TP is designed
to replace thymidine phosphorylase in a sustained manner to reduce or eliminate elevated plasma
thymidine and deoxyuridine concentrations. Pre-clinical studies have shown that thymidine and
deoxyuridine diffuse across the erythrocyte membrane into the cell, where the encapsulated enzyme
catalyses its metabolism to the normal products (thymine and uracil). This should result in a
withdrawal of thymidine and deoxyuridine from the cellular compartments, and an amelioration of
the intra mitochondrial deoxyribonucleotide imbalances. We hypothesise that by preventing further
damage to mtDNA, mitochondrial turnover should allow mitochondrial regeneration, and thus the
restoration of mitochondrial function [22]. As an exploratory objective, this study will also assess
markers of mitochondrial condition, e.g., FGF21, GDF15, including mtDNA, mRNA, miRNA, and
lipidomics/proteomics, and the potential effects of reducing thymidine and deoxyuridine levels on
these markers. The pharmacodynamic and clinical data from the retrospective HSCT study supports
the hypothesis that biochemical improvement results in clinical improvement, particularly in BMI, and
supports the use of pharmacodynamic data as a biomarker for clinical efficacy [13].
Due to the absence of previous data on outcome measures in MNGIE, validated secondary outcome
measures, including a quality of life measure, have been selected on the basis of clinical trials in
similar disorders. We have chosen not to composite outcome measures due to the marked phenotypic
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variability of the disorder. No validated composite outcome measure exists for MNGIE. Using
assessment/rating scales for mitochondrial disorders more generally (e.g., the Newcastle Mitochondrial
Disease Assessment Scale) would be a risk in a very small population, with composite outcomes
showing no effect overall, while a more critical individual measure (e.g., BMI, or mortality), would
show evidence of benefit [23].
There are generally no accepted endpoints for clinical studies in patients with MNGIE. This
ultra-rare disease usually presents with a combination of cachexia, gastrointestinal dysfunction, and
neuromuscular dysfunction. Although weight loss is one of the key features of MNGIE and has a major
impact on functional status, individual weight loss trajectories are not typically available in published
case series. Weight loss is clearly associated with increased morbidity and mortality, and a decreased
quality of life in other chronic diseases for which weight loss is a primary manifestation, including
cancer [24], chronic obstructive pulmonary disease [25], chronic heart disease [26], chronic kidney
disease [27], and acquired immunodeficiency syndrome [28]. Overall, current evidence shows that
weight loss is a valid prognostic marker and is associated with decreased quality of life across different
conditions. Additionally, at least in patients with cancer, weight loss and symptoms associated with
anorexia cachexia have been shown to have a psychosocial effect, not only on patients, but also on the
caregivers and families of those affected [29].
Weight is an objective measurement, which is readily obtained without causing additional burden
to patients. Objectiveness is a critical requirement within the context of the planned open label design
of this study. Serial measurements of body weight offer the simplest screen for nutritional adequacy
and change in nutritional status. The weight and height of a patient are used to formulate the BMI (i.e.,
calculated by an individual’s body mass divided by the square of his/her height (kg/m2)). Since weight
loss is essentially a universal feature of MNGIE, any weight gain is highly likely to represent a very
sensitive clinical objective. Consequently, the primary clinical endpoint in this study will be mean
absolute change from baseline in BMI.
Most published case series show a mean BMI of approximately 14 kg/m2 in patients with MNGIE,
e.g., reference [4] describes 35 patients of which 16 were living at the time. The average height
and weight for males were 170 cm and 40.3 kg, respectively, whilst for females were 159.1 cm and
35.5 kg. In the weight range reported for patients with MNGIE, an increase in BMI of approximately
0.2 represents an increase in body weight of approximately 0.5 kg. This increase is well above the
measurement error for medical grade scales and is likely to be above intra individual variation for
human weights in the low range. Therefore, an increase in BMI of 0.2 kg/m2 will empirically be used
as a minimum threshold in counting patients with weight increase. Owing to the extreme rarity of the
occurrence of MNGIE, a stabilisation of ±0.2 kg/m2 in BMI will be deemed to be clinically significant,
rather than statistically significant, since it is expected to halt further clinical deterioration. Weight loss
is clearly associated with increased morbidity and mortality in a variety of other chronic conditions.
If adult patients with MNGIE were able to maintain or slightly increase their BMI with long-term
therapy with EE-TP, this stabilisation would highly likely manifest itself in decreased overall morbidity
and mortality, and hence overall clinical benefit in this population.
There is limited precedent for weight measurement following intervention for patients with
MNGIE. In a retrospective international study of 24 patients with MNGIE treated with HSCT, 7 patients
survived more than two years after HSCT, and all gained weight (median weight increase was 2.5 kg at
a median follow-up of 53 months) [13]. This weight gain occurred in parallel with increase in TP activity
to normal levels and normalisation of thymidine and deoxyuridine levels. Due to the retrospective
international nature of the study, no consistent formal clinical outcome measures were documented.
Subjective evaluation of clinical examination in two year survivors suggested improvements in muscle
strength and sensation, although this was not quantified. A patient who received orthotopic liver
transplantation for MNGIE was reported to have cachexia and body mass/BMI monitored, although
no improvement was noted [30].
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Treatments targeting anorexia and cachexia in other disorders, such as oxandrolone, dronabinol,
megestrol acetate, growth hormone, and anamorelin, have previously used weight gain, with lean body
mass and handgrip strength being used more recently. The mechanism of action of those products,
targeting appetite and hormonal control of food intake, suggests that they would not be effective in
patients with MNGIE.
Likewise, there is no systematic information on the illness experience of patients with MNGIE,
and no disease specific instrument to collect it. The disease is a multi-system organ disorder with a
heterogeneous presentation. Secondary outcome measures have been selected to assess gastrointestinal
and peripheral sensorimotor polyneuropathy symptoms. The selected instruments are not disease
specific, but have been shown to correlate significantly with both generic and disease targeted legacy
instruments, and demonstrate evidence of reliability [31]. In addition, patient global impression of
improvement, as well as improvement of the most disabling symptom for each patient, will be assessed.
The precise mechanism through which correction of the enzymatic defect through EE-TP therapy
can decrease the elevated circulating levels of thymidine and deoxyuridine, ultimately restoring
gastrointestinal function leading to an increase and stabilisation in body weight and improved
outcomes, is speculative at this point. Previous research has shown that severe depletion of mtDNA is
the main molecular defect in the gut wall of patients with MNGIE [21,32]. The depletion of mtDNA
correlates with histopathological abnormalities and is likely due to toxic levels of thymidine and
deoxyuridine disrupting the mitochondrial nucleotide pool through an unknown mechanism. The
reduction of circulating levels of thymidine and deoxyuridine could, in principle, prevent further
mtDNA depletion and, in time, promote the restoration of depleted gastrointestinal smooth muscle
mtDNA pools. The consequent potential improvement of intestinal motility and improvement of
nutrient absorption can be hypothesised to at least prevent further deterioration of the nutritional
status and reduce gastrointestinal symptoms.
In summary, cachexia is the most consistent clinical manifestation of MNGIE. A robust clinical
outcome measure of mean absolute change in BMI from baseline at 24 months is the primary endpoint.
Stabilisation in BMI over a 24 month period will be regarded as a significant clinical benefit based on
the consistent loss in BMI with time in patients with MNGIE. Relevant secondary endpoints included
are the proportion of patients who require TPN, handgrip strength (using a dynamometer, according
to the Southampton protocol), functional disability assessed by RODS, 10 m walk test, evaluation of
gastrointestinal symptoms (PROMIS short form), neurological examination (for the assessment of
presentation, improvement, or worsening in motor strength, distal sensory impairment, or areflexia),
PGIC, assessment of the most disabling symptom for each patient using VAS, and quality of life. This
range of secondary outcome measures will enable capture of clinical effect in a condition for which
there is considerable phenotypic variability.
4. Conclusions
To conclude, the open label, multiple dose design of this study will allow maximal data
contributions from each patient in this ultra-rare indication, and offer sufficient flexibility to make
use of continuously emerging knowledge that is generated as the study progresses. The design also
incorporates safe progression of exposure, with multiple checks and provisions, ensuring risk is
managed appropriately, i.e., all patients will receive the lowest dose of EE-TP for the first two doses
with 24 h observation following exposure to the first four doses and Patient Oversight Committee
recommendation regarding dose progression.
5. Patents
Bax, B.E and Bain, M.D. (2018) Treatment for mitochondrial neurogastrointestinal
encephalomyopathy (MNGIE). EP2760459B1.
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